Additional Information (definitive) (defa14c)
November 29 2021 - 4:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
14C INFORMATION
Information
Statement Pursuant to Section 14(c)
of
the Securities Exchange Act of 1934
Check
the appropriate box:
☐
|
Preliminary
Information Statement
|
|
|
☐
|
Confidential,
for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))
|
|
|
☐
|
Definitive
Information Statement
|
|
|
☒
|
Definitive
Additional Materials
|
YEW
BIO-PHARM GROUP, INC.
(Name
of Registrant as Specified In Its Charter)
Payment
of Filing Fee (Check the appropriate box):
☒
|
No
fee required.
|
|
|
☐
|
Fee
computed on table below per Exchange Act Rules 14c-5(g) and 0-11.
|
|
1)
|
Title
of each class of securities to which transaction applies:
|
|
2)
|
Aggregate
number of securities to which transaction applies:
|
|
3)
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined):
|
|
4)
|
Proposed
maximum aggregate value of transaction:
|
☐
|
Fee
paid previously with preliminary materials.
|
|
|
☐
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its
filing.
|
|
1)
|
Amount
Previously Paid:
|
|
2)
|
Form,
Schedule or Registration Statement No.:
|
YEW
BIO-PHARM GROUP, INC.
9460
Telstar Avenue, Suite 6
El
Monte, California 91731
NOTICE
OF INTERNET AVAILABILITY OF INFORMATION STATEMENT MATERIALS
AND
FORM
10-K FOR THE YEAR 2020
To
Our Stockholders:
An
Information Statement is being made available by the Board of Directors of Yew Bio-Pharm Group, Inc., a Nevada corporation (the “Company”),
to holders of record of the Company’s common stock at the close of business on November 15, 2021 (the “Record Date”).
The purpose of this Information Statement is to inform the Company stockholders of the following actions taken by written consent of
the holders of a majority of the Company’s voting stock, dated November 15, 2021:
|
1.
|
To
elect five (5) directors to serve until the next Annual Meeting of Shareholders and thereafter until their successors are elected
and qualified; and
|
|
2.
|
To
grant the Board of Directors the discretionary authority to amend the Company’s articles of incorporation to affect a reverse
stock split of the Company’s common stock (“Common Stock”) in a range of not less than five (5) shares and not
more than ten (10) shares, into one share of Common Stock at any time prior to September 30, 2022 (the “Reverse Stock Split
Proposal”); and
|
|
3.
|
A
proposal to ratify the appointment of Simon & Edward, LLP as the Company’s independent registered public accounting firm
for the fiscal year ending December 31, 2021.
|
The
foregoing actions were approved on November 15, 2021 by our Board of Directors. In addition, on November 15, 2021 the holders of 52.1%
of the Company’s outstanding voting securities, as of the Record Date approved the foregoing actions. The number of shares voting
for the proposals was sufficient for approval.
Section
78.320 of the Nevada Revised Statutes (the “NRS”) provides in part that any action required or permitted to be taken at a
meeting of the stockholders may be taken without a meeting if, before or after the action, a written consent thereto is signed by stockholders
holding at least a majority of the voting power, except that if a different proportion of voting power is required for such an action
at a meeting, then that proportion of written consents is required.
Important
Notice Regarding the Availability of Information Statement Materials and the Form 10-K
Pursuant
to Securities and Exchange Commission Rule §240.14C-2, you are receiving this notice that the Information Statement and Annual report
on Form 10-K are available on the Internet. This communication provides only a brief overview of the more complete Information Statement
Materials. We encourage you to access and review all of the important information contained in the Information Statement Materials.
Follow
the instructions below to view the materials or request printed or email copies.
Our
Information Statement and Annual Report on Form 10-K for the fiscal year ended December 31, 2020, are available at www.yewbiopharm.com/investors/annual-meeting/
If
you want to receive a paper or e-mail copy of these documents, you must request one. There is no charge to you for requesting a paper
or e-mail copy. Please make your request for a copy by one of the following methods on or before December 9, 2021 to facilitate timely
delivery.
-
|
E-mail
to hpang@speedlightcs.com
|
-
|
Mail
at Yew Bio-Pharm Group, Inc., 9460 Telstar Avenue, Suite 6, El Monte, CA 91731
|
-
|
Telephone
call to (626) 401-9588.
|
WE
ARE NOT ASKING FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.
|
By
Order of the Board of Directors,
|
|
|
|
/s/
Guifang Qi
|
|
Guifang
Qi, Chief Executive Officer
|
|
Dated:
November 29, 2021
|
Yew Bio Pharm (CE) (USOTC:YEWB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yew Bio Pharm (CE) (USOTC:YEWB)
Historical Stock Chart
From Apr 2023 to Apr 2024